Assessment of the Efficacy from a Novel Desensitising Gel Formulation
Objectives: The aim of this investigation was to determine clinical efficacy of a novel desensitizing gel containing 12% w/w strontium acetate over a period of 14 days. Material and Methods: Thirty-six subjects with pre-existing dentine hypersensitivity were included in this single center, monadic study. Following an approximate 14 day washout period, sensitivity assessments and questionnaire data were collected at baseline, Days 3 and 15. At baseline, subjects exhibiting at least two teeth with exposed dentine surfaces with qualifying evaporative (air) score of > 30 mm on a Visual Analogue Scale (VAS) and a tactile (Yeaple probe) score of T 40 grams of force were enrolled on the study. Routine oral hygiene measures of twice daily brushing with a regular family dentifrice (Crest Cavity Protection) were continued throughout the study. Subjects were provided with a novel 12% w/w Strontium Acetate containing desensitising gel treatment to be used twice daily. The subject applied a small amount onto their finger or cotton swab and gently massaged the exposed dentine area. Results: At both Days 3 and 15, there was a statistically significant reduction in tooth sensitivity from baseline observed in group mean evaporative air VAS scores of 9.52 mm (15.43%; p=0.0001), 25.68 mm (41.63%; p<0.0001) respectively. In addition, there was a statistically significant increase in mean tactile threshold from baseline (indicating a reduction in sensitivity) observed at Day 3, 4.70 grams (p=0.0039) and Day 15, 15.16 grams (p<0.0001). None of the five adverse events reported during the study were determined to be related to product use. Conclusions: In this pilot study, the novel strontium containing desensitizing gel for treatment of hypersensitive dentine surfaces was determined to be an easy, safe and effective alternative providing significant relief from dentine hypersensitivity.
Division: British Division Meeting
Meeting:2009 British Division Meeting (Glasglow, Scotland) Location: Glasglow, Scotland
Year: 2009 Final Presentation ID:153 Abstract Category|Abstract Category(s):Scientific Groups
Authors
Maggio, Brenda
( GlaxoSmithKline Consumer Healthcare, Surrey, N/A, United Kingdom
)
Bannon, Linda
( GlaxoSmithKline Consumer Healthcare, Surrey, N/A, United Kingdom
)